{
    "clinical_study": {
        "@rank": "4833", 
        "arm_group": [
            {
                "arm_group_label": "Ketamine treated", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Control, placebo treated", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "A randomized multicentric parallel arms study involving the use of ketamine for\n      treatment-resistant depression will be held at three national health provider clinics in the\n      Mexican population. The purpose of this study is to determine whether clinical response seen\n      in previous studies is replicable in this population."
        }, 
        "brief_title": "Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population", 
        "condition": [
            "Depressive Disorder,", 
            "Treatment-Resistant Depression"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Depression", 
                "Depressive Disorder"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age: 18-65 years old\n\n          -  Mayor Depressive Disorder Diagnosis based on DSM-IV TR.\n\n          -  Classification of MDD as treatment-resistant.\n\n          -  No brain structural abnormalities as evidenced by an MRI scan.\n\n          -  Signed acceptance of Informed Consent.\n\n        Exclusion Criteria:\n\n          -  Other psychiatric diagnosis apart from MDD.\n\n          -  Substance abuse or dependence (prior or during study).\n\n          -  Pregnancy.\n\n          -  Congestive heart disease.\n\n          -  Personal history of psychosis.\n\n          -  First-degree relative with history of psychosis.\n\n          -  Glaucoma.\n\n          -  Present neurological disease.\n\n          -  High blood or pulmonary artery pressure.\n\n          -  Declining the signing of the informed consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01868802", 
            "org_study_id": "ABC KET-DRT-01-2013"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ketamine treated", 
                "description": "A single dose of 0.5mg/kg intravenous ketamine infusion will be administered over 40 minutes.", 
                "intervention_name": "Ketamine", 
                "intervention_type": "Drug", 
                "other_name": "Ketalar"
            }, 
            {
                "arm_group_label": "Control, placebo treated", 
                "description": "Saline at 0.9% intravenous infusion will be administered over 40 minutes.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ketamine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Ketamine", 
            "Depression", 
            "Depressive Disorder"
        ], 
        "lastchanged_date": "September 13, 2013", 
        "location": {
            "contact": {
                "email": "esanesteban@hotmail.com", 
                "last_name": "Eduardo San Esteban, M.D.", 
                "phone": "+52 (55) 52308000"
            }, 
            "facility": {
                "address": {
                    "city": "Mexico City", 
                    "country": "Mexico", 
                    "state": "DF", 
                    "zip": "05300"
                }, 
                "name": "ABC Neurological Center"
            }, 
            "investigator": {
                "last_name": "Paul J Lamothe Molina, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Mexico"
        }, 
        "number_of_arms": "2", 
        "official_title": "Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population", 
        "overall_contact": {
            "email": "paul@lamothe.com", 
            "last_name": "Paul J Lamothe, M.D.", 
            "phone": "+52 (55) 11031750"
        }, 
        "overall_contact_backup": {
            "email": "davidlopezgarza@prodigy.net.mx", 
            "last_name": "David N Lopez-Garza, M.D.", 
            "phone": "+ 52 (55) 11031750"
        }, 
        "overall_official": [
            {
                "affiliation": "American British Cowdray Medical Center", 
                "last_name": "Paul J Lamothe, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "National Institute of Neurology and Neurosurgery, Mexico", 
                "last_name": "Rodrigo Perez-Esparza, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "American British Cowdray Medical Center", 
                "last_name": "David N Lopez-Garza, M.D.", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "National Institute of Neurology and Neurosurgery, Mexico", 
                "last_name": "Jesus Ramirez-Bermudez, M.D.", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "American British Cowdray Medical Center", 
                "last_name": "Manuel Ruiz-Alvarez, M.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Mexico: Federal Commission for Sanitary Risks Protection", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The Hamilton Depression Rating Scale (HDRS) baseline score will be measured 20 minutes before ketamine infusion. After 40 minutes post-infusion, a second HDRS score will be obtained.", 
                "measure": "Changes in baseline HDRS Score", 
                "safety_issue": "No", 
                "time_frame": "20 minutes before and 40 minutes after ketamine infusion."
            }, 
            {
                "description": "On a daily basis, from day 1-7 post-ketamine infusion, changes in HDRS score will be measured during the daily psychiatric evaluation.", 
                "measure": "Daily change in HDRS post-ketamine infusion.", 
                "safety_issue": "No", 
                "time_frame": "1,2,3,4,5,6 and 7. Days after ketamine infusion"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01868802"
        }, 
        "responsible_party": {
            "investigator_affiliation": "American British Cowdray Medical Center", 
            "investigator_full_name": "Paul J. Lamothe", 
            "investigator_title": "Chief of the Research Department, Neurological Center.", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Baseline BP will be measured during the physical examination 20 minutes before ketamine infusion.", 
                "measure": "Baseline blood pressure (BP).", 
                "safety_issue": "Yes", 
                "time_frame": "20 minutes before ketamine infusion."
            }, 
            {
                "description": "BP will be monitored continuously for a 4-hour period. BP assessments will be taken every five minutes for the period mentioned. The assessment will start 20 minutes before ketamine administration and will finish 4hrs after starting.", 
                "measure": "Changes from baseline in blood pressure (BP)", 
                "safety_issue": "Yes", 
                "time_frame": "every 5 minutes in a 300 minutes period"
            }
        ], 
        "source": "American British Cowdray Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Paul J. Lamothe", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}